WO2006044421A3 - Cardiac safe, rapid medication delivery - Google Patents

Cardiac safe, rapid medication delivery Download PDF

Info

Publication number
WO2006044421A3
WO2006044421A3 PCT/US2005/036587 US2005036587W WO2006044421A3 WO 2006044421 A3 WO2006044421 A3 WO 2006044421A3 US 2005036587 W US2005036587 W US 2005036587W WO 2006044421 A3 WO2006044421 A3 WO 2006044421A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiac
safe
medication delivery
rapid
rapid medication
Prior art date
Application number
PCT/US2005/036587
Other languages
French (fr)
Other versions
WO2006044421A2 (en
Inventor
Joshua D Rabinowitz
Peter M Lloyd
Original Assignee
Alexza Pharmaceuticals Inc
Joshua D Rabinowitz
Peter M Lloyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexza Pharmaceuticals Inc, Joshua D Rabinowitz, Peter M Lloyd filed Critical Alexza Pharmaceuticals Inc
Priority to EP05812408A priority Critical patent/EP1809240A4/en
Publication of WO2006044421A2 publication Critical patent/WO2006044421A2/en
Publication of WO2006044421A3 publication Critical patent/WO2006044421A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The disclosure provides methods and compositions for providing an effective dose of an active agent and/or drug composition to a subject by inhalation. The methods of the disclosure are useful in determining a maximal effective dose that limits cardiovascular damage upon inhalation.
PCT/US2005/036587 2004-10-12 2005-10-12 Cardiac safe, rapid medication delivery WO2006044421A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05812408A EP1809240A4 (en) 2004-10-12 2005-10-12 Cardiac safe, rapid medication delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61824304P 2004-10-12 2004-10-12
US60/618,243 2004-10-12
US71276005P 2005-08-30 2005-08-30
US60/712,760 2005-08-30

Publications (2)

Publication Number Publication Date
WO2006044421A2 WO2006044421A2 (en) 2006-04-27
WO2006044421A3 true WO2006044421A3 (en) 2006-08-03

Family

ID=36203466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036587 WO2006044421A2 (en) 2004-10-12 2005-10-12 Cardiac safe, rapid medication delivery

Country Status (3)

Country Link
US (1) US20060120962A1 (en)
EP (1) EP1809240A4 (en)
WO (1) WO2006044421A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US7078016B2 (en) * 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
ATE415155T1 (en) * 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM, OR TRIAZOLAM BY INHALATION
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
JP2006514934A (en) 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド Use of loxapine or amoxapine for the manufacture of drugs for the treatment of pain
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CA2507158A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
ATE510174T1 (en) * 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc IMPACT LIT INDEPENDENT HEATING UNIT
US20050034723A1 (en) * 2003-08-04 2005-02-17 Bryson Bennett Substrates for drug delivery device and methods of preparing and use
US7402777B2 (en) 2004-05-20 2008-07-22 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20080299048A1 (en) * 2006-12-22 2008-12-04 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositions
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20100065052A1 (en) * 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20100300433A1 (en) * 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
CA2822738C (en) 2010-12-22 2021-06-08 Exonoid Medical Devices Ltd. Method and system for drug delivery
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
JP6397493B2 (en) 2013-07-11 2018-09-26 アレックザ ファーマシューティカルズ， インコーポレイテッド Nicotine salt with meta-salicylic acid
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
AU2015283590B2 (en) 2014-06-30 2020-04-16 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3160565B1 (en) * 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3160553B1 (en) 2014-06-30 2021-10-20 Syqe Medical Ltd. Device for vaporization and inhalation of isolated substances
RU2723335C2 (en) 2014-06-30 2020-06-09 Сике Медикал Лтд. Dose cartridge for inhaler
DK3160558T3 (en) 2014-06-30 2020-04-27 Syqe Medical Ltd FLOW CONTROL INHALING DEVICE
CN114522307A (en) 2015-03-11 2022-05-24 艾利斯达医药品公司 Use of antistatic materials in airways for hot aerosol condensation processes
CA2991108A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
WO2017118980A1 (en) 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
SG10202012584UA (en) 2016-02-01 2021-01-28 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
JP7072578B2 (en) * 2016-10-03 2022-05-20 ジョルジ ネヴァル モル ネト， Devices, systems and methods for coffee-derived volatiles
RS65112B1 (en) * 2016-12-09 2024-02-29 Alexza Pharmaceuticals Inc Alprazolam for use in treating epilepsy
KR20200003199A (en) 2017-05-10 2020-01-08 인카다 테라퓨틱스, 인크. Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN114822876B (en) * 2022-06-14 2023-07-21 湖南慧泽生物医药科技有限公司 Predictive model, device and storage medium for drug absorption rate constant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017120A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of erectile dysfunction drugs through an inhalation route

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507158A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017120A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of erectile dysfunction drugs through an inhalation route

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOCHHAUS G. ET AL.: "Pharmacokinetic/Dynamic Correlation of Pulmonary and Cardiac Effects of Fenoterol in Asthmatic Patients After Different Routes of Administration", PHARMACEUTICAL RESEARCH, vol. 9, no. 3, 1992, pages 291 - 297, XP008085060 *
THOMSON P.D.R.: "Physican's Desk Reference", vol. 57TH ED., 2003, MONTVALE, NJ, pages: 1542 - 1550, XP008085040 *

Also Published As

Publication number Publication date
EP1809240A2 (en) 2007-07-25
US20060120962A1 (en) 2006-06-08
EP1809240A4 (en) 2010-06-16
WO2006044421A2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2006031878A3 (en) Imidazoquinoline compounds
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
EP2279726A3 (en) Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
WO2009125981A3 (en) Pharmaceutical formulation
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2006121522A3 (en) Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2008106689A3 (en) Breakthrough pain management
WO2007133944A3 (en) Topical administration of acyclovir

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005812408

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005812408

Country of ref document: EP